MedPath logo

NUTRINEAL PD4 WITH 1.1% AMINO ACID SOLUTION

General Sale List
Drug type: Therapeutic
ATC code: B05DA
Dosage form: SOLUTION, STERILE
Route of administration: INTRAPERITONEAL
Active ingredient: L-ISOLEUCINE; L-VALINE; CALCIUM CHLORIDE DIHYDRATE; MAGNESIUM CHLORIDE HEXAHYDRATE; L-SERINE; GLYCINE; L-TRYPTOPHAN; SODIUM LACTATE; L-LYSINE (as HCl); SODIUM CHLORIDE; L-PHENYLALANINE; L-METHIONINE; L-TYROSINE; L-PROLINE; L-THREONINE; L-HISTIDINE; L-ARGININE; L-LEUCINE; L-ALANINE; CALCIUM CHLORIDE DIHYDRATE; GLYCINE; L-ALANINE; L-ARGININE; L-HISTIDINE; L-ISOLEUCINE; L-LEUCINE; L-LYSINE (as HCl); L-METHIONINE; L-PHENYLALANINE; L-PROLINE; L-SERINE; L-THREONINE; L-TRYPTOPHAN; L-TYROSINE; L-VALINE; MAGNESIUM CHLORIDE HEXAHYDRATE; SODIUM CHLORIDE; SODIUM LACTATE

1. Therapeutic Indications

Nutritional supplement for malnourished renal failure patients (albumin concentration lower than 35g/litre) being maintained on peritoneal dialysis.

3. Contraindication

NUTRINEAL is contraindicated in patients with:

  • known hypersensitivity to any amino acids in the product or to any of the excipients
  • Serum urea level above 38mmol/L
  • uremic symptoms
  • metabolic acidosis
  • inborn errors of amino acid metabolism
  • liver insufficiency
  • severe hypokalemia
  • uncorrectable mechanical defects that prevent effective PD or increase the risk of infection
  • documented loss of peritoneal function or extensive adhesions that compromise peritoneal function

2. Dosage and Method of Administration

Administration:

  • NUTRINEAL is intended for intraperitoneal administration only. Not for intravenous administration.
  • The intraperitoneal administration route requires the use of a specific peritoneal dialysis catheter and an appropriate administration set which connects the solution container to the patient's catheter.
  • NUTRINEAL should be administered at a rate that is comfortable for the patient. The volume administered is determined by the prescribing physician.
  • The mode of therapy, frequency of treatment, exchange volume, duration of dwell and length of dialysis should be initiated and supervised by the prescribing physician.
  • Treatment should be re-evaluated after 3 months if there is no clinical or biochemical improvement in the status of the patient.
  • Do not remove unit from over pouch until ready for use.
  • Peritoneal dialysis solutions may be warmed in the overpouch to 37°C (98.6°F) to enhance patient comfort. However, only dry heat (for example, heating pad, warming plate) should be used. Solutions should not be heated in water or in a microwave oven due to the potential for patient injury or discomfort.
  • Aseptic technique should be employed through the peritoneal dialysis procedure.
  • Do not administer unless the solution is clear and free of particulate matter.
  • In case of damage, the container should be discarded.
  • Discard any unused remaining solution
  • For single use only

Dosage:

  • Dosage schedule, frequency of treatment and duration of dwell should be selected by the prescribing physician according to the patient's clinical status.
  • Recommended dietary allowance of protein is approximately 1.2–1.3 g/kg for dialysed adults and 2–3 g/kg for infants. Higher amounts may be necessary in several catabolic states.
  • For information, a 2-litre bag of Nutrineal with 1.1% amino acids provides 22g of amino acids which are equivalent to 0.30g/kg/day for a 70kg adult.
  • Safety and effectiveness in pediatric patients has not been established.
Registrant
BAXTER HEALTHCARE (ASIA) PTE LTD
Approval Date
1997-05-27
Approval Number
SIN09353P
Manufacturer
BAXTER HEALTHCARE SA, SINGAPORE BRANCH BAXTER HEALTHCARE SA
Licence Holder
BAXTER HEALTHCARE (ASIA) PTE LTD